Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy2018-01-17T17:06:09-05:00
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy2018-01-17T17:06:02-05:00
Bias, not conflict of interest, is the enemy Bias, not conflict of interest, is the enemy2018-01-17T17:05:56-05:00
Preventive Medicine, Properly Practiced Preventive Medicine, Properly Practiced2018-01-17T17:05:56-05:00
Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS2018-01-17T17:05:43-05:00
Interferon beta in multiple sclerosis: how much BENEFIT? Interferon beta in multiple sclerosis: how much BENEFIT?2018-01-17T17:05:43-05:00
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis2018-01-17T17:05:43-05:00
Is nalalizumab a breakthrough in the treatment of MS? Is nalalizumab a breakthrough in the treatment of MS?2018-01-17T17:05:43-05:00
Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol2018-01-17T17:05:35-05:00
